Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data

Quanfeng Zhao,Pan Ma,Peishu Fu,Jiayu Wang,Kejing Wang,Lin Chen,Yang Yang
DOI: https://doi.org/10.3389/fphar.2022.990048
IF: 5.6
2022-08-11
Frontiers in Pharmacology
Abstract:[This corrects the article DOI: 10.3389/fphar.2022.912256.].
pharmacology & pharmacy
What problem does this paper attempt to address?